Peripheral and Coronary Endothelial Dysfunction In Type 2diabetic Patients- Role of Metformin

Civil Hospices of Lyon

Status and phase: Terminated; Phase 3

Conditions: Coronary and Peripheral Endothelial Dysfunction

Treatments: Drug: Gliclazide; Drug: Metformin

Study type: Interventional

Funder types: Other

Identifiers

NCT00169624

2004.346

Details and patient eligibility

About

Peripheral and coronary endothelial dysfunction in type 2 diabetic patients may be influenced by therapeutics. Using Radial flow monitoring and myocardial perfusion magnetic resonance imaging, we designed a controlled randomized double blind study to test the hypothesis that endothelial dysfunction will be reversed following 3 months of Metformin administration vs gliclazide. 30 patients will be included.

Sex: All

Ages: 18 to 70 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

18-70 years old, type 2 diabetes, non significant coronary atherosclerosis on inclusion coronary angiogram (ie no coronary stenosis > 70%), HbA1c<9%

Exclusion criteria

significant coronary stenosis (>70%), lack of informed consent, unstable hypertension, renal failure, contra-indication to metformin or gliclazide, pregnancy, atrial fibrillation, contraindication to MRI, or to adenosine, brachial artery calcifications